24/7 Market News Snapshot 06 August, 2025 – Geron Corp (NASDAQ:GERN)

August 6, 2025

DENVER, Colo., 06 August, 2025 (www.247marketnews.com) – (NASDAQ:GERN) are discussed in this article.
Geron Corporation has demonstrated a significant uptick in market performance, with shares rising approximately 12.08% to trade at $1.345, following a previous close at $1.20. This notable increase has generated heightened investor interest, evidenced by a trading volume of 22.17 million shares, illustrating robust market engagement. Analysts are observing key technical indicators showcasing bullish momentum as the stock continues to break through important resistance levels. Traders are advised to monitor support around the $1.30 mark, as sustained performance above current levels could herald additional upward movement, while a dip below may signal potential market corrections.

Concurrently, Geron has announced impressive financial results for the second quarter of 2025, reporting net product revenue of $49.0 million—a 24% increase compared to the prior quarter. This growth can largely be attributed to a 17% rise in demand for its innovative therapy, RYTELO (imetelstat), with the company seeing nearly quadruple expansion in ordering accounts since the beginning of the year. Geron is strategically prepping for the anticipated launch of RYTELO in select European markets, leveraging the momentum gained domestically.

Additionally, Harout Semerjian has been appointed as the new President and CEO, effective immediately. His leadership is expected to align with Geron’s strategic goals for promoting RYTELO’s market success. Dawn Carter Bir, the Interim CEO, expressed optimism about the company’s trajectory, especially with regards to its bolstered commercial sales and expanded medical science initiative.

Furthermore, Geron is nearing the completion of patient enrollment in its pivotal Phase 3 IMpactMF trial, focusing on imetelstat for relapsed or refractory myelofibrosis. An interim analysis is anticipated in the latter half of 2026. With projected operating expenses for the year estimated between $270 million and $285 million, Geron expects its existing resources to adequately sustain its growth initiatives moving forward.

Related news for (GERN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.